DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

NeOnc Technologies Holdings, Inc.

NasdaqGM:NTHI Stock Report

Market Cap: US$91.5m

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

NeOnc Technologies Holdings Past Earnings Performance

Past criteria checks 0/6

NeOnc Technologies Holdings's earnings have been declining at an average annual rate of -55%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been declining at an average rate of 36.7% per year.

Key information

-55.04%

Earnings growth rate

-47.29%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate-36.70%
Return on equityn/a
Net Margin-118,029.51%
Last Earnings Update30 Jun 2026

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Oct 09

NeOnc Technologies: From Survival Mode To Expansion Mode

Summary NeOnc Technologies Holdings is a micro-cap biotech focused on innovative brain cancer treatments, NEO100 and NEO212, both in early clinical trials. NTHI's financials are challenging, with no revenue, rising R&D expenses, and a significant cash burn, but a $50M Quazar partnership is set to transform its outlook. The Quazar deal will provide crucial funding, pay off debts, and enable NTHI to accelerate clinical development and expansion in the MENA region. Read the full article on Seeking Alpha

Revenue & Expenses Breakdown

How NeOnc Technologies Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:NTHI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 260-47366
31 Mar 260-39294
31 Dec 250-62554
30 Sep 250-49433
30 Jun 250-42384
31 Mar 250-41343
31 Dec 240-1243
30 Sep 240-1643
30 Jun 240-1742
31 Mar 240-1542
31 Dec 230-1542
30 Sep 230-1041
30 Jun 230-731
31 Mar 230-521
31 Dec 220-321

Quality Earnings: NTHI is currently unprofitable.

Growing Profit Margin: NTHI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NTHI is unprofitable, and losses have increased over the past 5 years at a rate of 55% per year.

Accelerating Growth: Unable to compare NTHI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NTHI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1%).


Return on Equity

High ROE: NTHI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 04:14
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NeOnc Technologies Holdings, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew VeneziaAlliance Global Partners
Thomas ShraderBTIG
Jason McCarthyMaxim Group

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide